Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | DPYD | Q12882 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38658521 | 0.86 | ATAD2 (0.47) | ATAD2MAPTALDH1A1LMNADPYD | |
| SCHEMBL7785411 | 0.75 | MAPT (0.40) | ATAD2POLBMAPTTP53ALDH1A1 | |
| SCHEMBL9468820 | 0.72 | ATAD2 (0.40) | ATAD2MAPTALDH1A1LMNADPYD | |
| SCHEMBL1918404 | 0.69 | ATAD2 (0.52) | ATAD2MAPTALDH1A1LMNADPYD | |
| SCHEMBL1144951 | 0.68 | ATAD2 (0.39) | ATAD2DPYD | |
| SCHEMBL30132229 | 0.67 | POLB (0.39) | ATAD2POLBMAPTTP53ALDH1A1 | |
| SCHEMBL5800258 | 0.67 | ATAD2 (0.41) | ATAD2MAPTALDH1A1LMNADPYD | |
| SCHEMBL16893950 | 0.67 | GAA (0.54) | ATAD2MAPTALDH1A1LMNADPYD | |
| SCHEMBL887700 | 0.66 | ATAD2 (0.48) | ATAD2MAPTALDH1A1LMNADPYD | |
| SCHEMBL8933555 | 0.66 | GAA (0.48) | ATAD2POLBMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194597-B1 | ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES | UNIV BRITISH COLUMBIA (CA) | 2021-06-30 | — | — | EP | disclosed |
| US-10731160-B2 | Allele-specific therapy for Huntington disease haplotypes | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-08-04 | — | — | US | disclosed |
| US-20200199595-A1 | ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-06-25 | — | — | US | disclosed |
| US-20170253877-A1 | ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-09-07 | — | — | US | disclosed |
| EP-3194597-A1 | ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES | The University Of British Columbia (CA) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017000058-A1 | MODULATION OF CYP8B1 FOR THE PREVENTION AND TREATMENT OF LIVER FIBROSIS AND METABOLIC DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016041058-A1 | ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-03-24 | — | — | WO | disclosed |
| US-9157120-B2 | Methods and compositions for the treatment of huntington's disease | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-13 | — | — | US | disclosed |
| US-20140256578-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-11 | — | — | US | disclosed |
| US-8679750-B2 | Methods and compositions for the treatment of Huntington'S disease | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-03-25 | — | — | US | disclosed |
| US-20110213010-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-01 | — | — | US | disclosed |
| EP-2297341-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | The University Of British Columbia (CA) | 2011-03-23 | — | — | EP | disclosed |
| US-20110038888-A1 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER | NVENTA BIOPHARMACEUTICALS CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-2247308-A1 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER | Nventa Biopharmaceuticals Corporation (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-2125853-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | Nventa Biopharmaceuticals Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009135322-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | THE UNIVERSTITY OF BRITISH COLUMBIA (CA) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009086640-A1 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER | NVENTA BIOPHARMACEUTICALS CORPORATION (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090041809-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | NVENTA BIOPHARMACEUTICALS CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008106803-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | NVENTA BIOPHARMACEUTICALS CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041809-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | EIF2AK2, TLR9, ADAR | ATAD2 888/4885POLB 194/4885MAPT 4200/4885 |
| US-20110038888-A1 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER | TLR3, PARG, TLR9 | ATAD2 3539/4885POLB 581/4885MAPT 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.